View in EDS

119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial

Saved in:
Bibliographic Details
Title: 119O Event-free survival (EFS), overall survival (OS), and safety of adding veliparib (V) plus carboplatin (Cb) or carboplatin alone to neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) after ≥4 years of follow-up: BrighTNess, a randomized phase III trial
Authors: Loibl, S.1 (AUTHOR), Sikov, W.2 (AUTHOR), Huober, J.3 (AUTHOR), Rugo, H.S.4 (AUTHOR), Wolmark, N.5 (AUTHOR), O'Shaughnessy, J.6 (AUTHOR), Maag, D.7 (AUTHOR), Untch, M.8 (AUTHOR), Golshan, M.9 (AUTHOR), Lorenzo, J. Ponce10 (AUTHOR), Metzger, O.11 (AUTHOR), Dunbar, M.12 (AUTHOR), Symmans, W.F.13 (AUTHOR), Geyer, C.14 (AUTHOR)
Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS408-S408. 1p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first